Lund, Sweden — 10 October 2018 — Camurus (Nasdaq Stockholm; CAMX) today announced that that the Company will present at the Jefferies 2018 London Healthcare Conference 14 November at 4:40 pm local time (GMT). Fredrik Tiberg, President and CEO, will update on the progress of the development pipeline, including the launch preparations for Buvidal® (CAM2038) in Europe, Australia and the US.
A webcast of the presentation can be accessed via wsw.com/webcast/jeff115/camx/.
Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
For more information
Fredrik Joabsson, VP Business Development
Tel. +46 (0)70 776 17 37
This information was submitted for publication at 08.00 am CET on 10 October 2018.